GB Sciences Names Business and Public Policy Expert as Special Advisor to the CEO
October 1st, 2014
GrowBLOX Sciences, Inc., a.k.a. GB Sciences (GBLX), a cannabinoid therapy research and development firm, has appointed Peter Emerson to serve as the senior advisor to CEO Craig Ellins. In this role, Emerson will work closely with Ellins on a wide range of policy issues primarily to ensure that treatments are uniform in purity, consistency, and potency, just like any other medicine.
“We have the science, the technology, and the right team to elevate cannabinoid therapies to precisely target debilitating medical conditions,” said Ellins. “Peter Emerson will facilitate our expansion so that we are able to help patients across the country.”
For over forty years, Emerson has helped shape public policy while serving as a senior executive in the US government and during his work with national and international clients. At GB Sciences he will draw upon his experience spearheading strategic communications, marketing, public relations, and advertising initiatives for individuals, corporations, and nonprofit organizations.
“I could not be more pleased to join a company that is seeking to provide evidence-based and medically sound cannabinoid therapies to those afflicted with such wide-ranging chronic conditions as Parkinson’s, epilepsy, and pain,” said Emerson.
Emerson stays active in both the private sector and academia. In addition to his business pursuits, Emerson serves as Associate for Public Policy at Cambridge Health Alliance’s Division on Addiction, a teaching affiliate of Harvard Medical School, and as Chairman of the Task Force on College Gambling Policies.
He also serves as a member of the Board of Directors of the Southern African Enterprise Development Fund, a one-hundred-million-dollar fund created by President Clinton at the urging of Nelson Mandela to foster economic growth and promote the creation of jobs in the Southern African region.
Emerson has contributed op-ed pieces to the New York Times, the Wall Street Journal, and the Boston Globe, as well as postings to the Huffington Post.
He graduated magna cum laude from New York University with a BA and from Harvard Kennedy School of Government with an MPA.
To learn more about GB Sciences, Inc., go to www.gbsciences.com.
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc.—aka GB Sciences (GBLX)—is a biotechnology research and development company focused on creating safe, standardized pharmaceutical-grade cannabinoid therapies that are effective in targeting and treating a variety of medical conditions. The company’s pioneering technology, proven processes, and perennial clinical research and development loop enable in-state entities the ability to bring relief to patients in their communities.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.